Besides, BTN3A2 also plays an important role in activating the phosphoantigen-mediated Vγ9Vδ2 T cells toward the development of pancreatic ductal adenocarcinoma (PDAC), implicating it as a promising immunotherapeutic target for the treatment of PDAC (Benyamine et al., 2017). The gene discussed is BTN3A2; the disease is pancreatic ductal adenocarcinoma.